In an amended 13D filing on PDL BioPharma Inc. (NASDAQ:PDLI), Dan Loeb's Third Point LLC disclosed an 8.8% stake (10.1 million shares) in the company. This is up from the 7.5% stake (8.6 million shares) in the original 13D filing.
Loeb also disclosed a new letter to the company's CEO, requesting four candidates be added to the Company's Board of Directors. Loeb also stated that he had been in discussions with a prominent consulting firm and that he would like the Board to retain that firm to review corporate and research and development spending. Loeb demanded, in the transmission, a definitive response from the CEO and the PDLI board, by the close of business on Thursday, March 22nd, as to whether they have agreed to add the four to the Board.